#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Bladder cancer Anti-neutrophil cytoplasmic antibody positive vasculitis Hyperinsulinaemic hypoglycaemia Stress cardiomyopathy Thrombocytosis Bulbospinal muscular atrophy congenital Lymphangioma Cutaneous T-cell lymphoma stage II Systemic scleroderma Oesophageal squamous cell carcinoma stage II Craniocerebral injury Antiphospholipid antibodies MELAS syndrome Endometrial cancer recurrent Osteogenesis imperfecta More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma refractory – Basic Information VEXAS syndrome – Diagnostics Tuberous sclerosis complex – Diagnostics Glycogen storage disease type V – Diagnostics Angiosarcoma non-metastatic – Basic Information Proteus syndrome – Life with Disease Langerhans’ cell histiocytosis – Life with Disease Mantle cell lymphoma stage IV – Trials in Disease Nephrotic syndrome – Basic Information Angiosarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rosuvastatin Zinc Furosemide Ph. Eur. Metyrapone ADS-019 Budesonide Albaconazole Nacubactam Decitabine Minzasolmin Enx-101 Piflufolastat (18F) Valsartan Calcium Chloride Volixibat CICLOPIROX Rifaximin Labetalol Hydrochloride Ertapenem Sodium GSKVX000000034795 Phleum Pratense (225) More therapies…

    Learn about Your Condition

    Tinnitus Plasmablastic lymphoma Bronchopulmonary aspergillosis Low cardiac output syndrome Biliary tract disorder Peritoneal cancer index Ocular hypertension Menopause Behavioural addiction Cerebral palsy Cirrhosis alcoholic Hepatic encephalopathy Major depression Skin angiosarcoma Tachypnoea More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Long-Term Safety and Efficacy of Oral Ribitol in Participants with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Ribitol
    Denmark Germany Italy The Netherlands Norway

  • Long‑Term Effects of Sirolimus on Volume and Color of Port‑Wine Stain in Patients with Vascular Malformation Undergoing Surgery and Laser Therapy

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Arteriovenous malformation
    Investigated Drugs:
    • Sirolimus
    Norway

  • Phase II Study of Teclistamab Plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma After 1–3 Prior Therapies

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Teclistamab
    • Pomalidomide
    Denmark Estonia Finland Norway

  • Evaluation of [68Ga]Ga-FAPI-46 PET Imaging for Staging and Detecting Disease Progression in Patients with Transthyretin Cardiac Amyloidosis

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Cardiac amyloidosis
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    France

  • Evaluation of gaxilose (LacTEST 0.45 g) as a marker of intestinal barrier integrity in patients with celiac disease

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Coeliac disease
    Investigated Drugs:
    • GAXILOSE
    Spain

  • Study of Topical Chloramphenicol vs Topical Ciprofloxacin for Treating Otorrhea in Adults with Chronic Suppurative Otitis Media

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Ciprofloxacin
    Spain
Previous Page
1 … 694 695 696 697 698 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!